TrialBlood advances2025

Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma.

Xian G Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.